# Providence Portland Medical Center
**Type:** Institutions
**Canonical URL:** https://scholariq.org/institutions/providence-portland-medical-center/
## Facts
| Field | Value |
| --- | --- |
| Avg h-index | 51.7 |
| Citations | 347,062 |
| City | Portland |
| Country | US |
| Description | Providence Portland Medical Center is a research organisation in Portland, US. OpenAlex records 3,070 works and 347,062 citations for it. 715 researchers list it as their most recent affiliation. |
| Homepage | http://oregon.providence.org/location-directory/p/providence-portland-medical-center/ |
| OpenAlex ID | https://openalex.org/I2801670537 |
| Region | Oregon |
| Researchers | 715 |
| ROR ID | https://ror.org/015tmw922 |
| Type | healthcare |
| Wikidata ID | https://www.wikidata.org/wiki/Q7252461 |
| Works | 3,070 |
## University collaborators
- [Johns Hopkins Medicine](https://scholariq.org/institutions/johns-hopkins-medicine/)
- [Johns Hopkins University](https://scholariq.org/institutions/johns-hopkins-university/)
## University papers
- [Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children](https://scholariq.org/papers/efficacy-of-larotrectinib-in-i-trk-i-fusion-positive-cancers-in-adults-and/)
- [Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer](https://scholariq.org/papers/lenvatinib-versus-placebo-in-radioiodine-refractory-thyroid-cancer/)
- [Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/overall-survival-benefit-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma](https://scholariq.org/papers/gp100-peptide-vaccine-and-interleukin-2-in-patients-with-advanced-melanoma/)
- [Efficacy of Selpercatinib in RET -Altered Thyroid Cancers](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-altered-thyroid-cancers/)
- [Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-in-patients-with-advanced-endometrial-cancer/)
- [Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study](https://scholariq.org/papers/pralsetinib-for-ret-fusion-positive-non-small-cell-lung-cancer-arrow-a-multi/)
- [Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort](https://scholariq.org/papers/nivolumab-monotherapy-and-nivolumab-plus-ipilimumab-in-recurrent-small-cell-lung/)
- [Pleural Fluid Chemical Analysis in Parapneumonic Effusions. A Meta-Analysis](https://scholariq.org/papers/pleural-fluid-chemical-analysis-in-parapneumonic-effusions-a-meta-analysis/)
- [Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/three-year-overall-survival-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-first-line-treatment-of/)
## University top topics
Showing 8 of 25.
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.